Fissure

• VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
• "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
• Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
• In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

• MC2-25 VLS is a novel treatment paradigm based on a di-peptide that inhibits carbamylation of amino acids and proteins in skin.
• MC2 Therapeutics believes that carbamylation of amino acids and proteins in the vulvar region by iso-cyanate is the root cause of VLS.
• The Phase 2 clinical trial is being conducted at multiple centres across Denmark and will evaluate the safety and efficacy of MC2-25 VLS in patients with VLS.
• The data generated from this double-blinded, placebo-controlled PoC trial will inform the trial design for a larger Phase 2b trial.

• Private equity (PE) backed CFOs are more concerned about holding onto their jobs than ever before, according to a newly released survey by Accordion , the private equity-focused financial and technology consulting firm.
• Findings from the firm’s third biannual survey, The State of the PE Sponsor & CFO Relationship , reveal that a whopping 91% of PE-backed CFOs say that they are worried about job security, representing a 25% increase since Accordion first reported on the statistic in 2019.
• The statistics beg the question: If CFOs and their sponsors are generally aligned, why are so many CFOs worried about their jobs?
• In addition to concerns about job security, three key takeaways emerged from this year’s results.

• The Chinese Communist Party has published regular communiques pushing Xi’s ideological line and When Marx met Confucius is the latest version of this propaganda drive.
• Its aim is to reconcile the regime’s official Marxist underpinnings with an appeal to a more specifically Chinese cultural heritage.
• This idea was introduced by Xi in July 2021, to mark the 100th anniversary of the Chinese Communist Party.
• Some analysts view Xi’s propaganda efforts through the lens of his steady encouragement of a cult of personality in China.

Challenges of legitimacy

• As Ci observes, the CCP “can have no other publicly avowable source of legitimacy than the one tied to its communist revolutionary past”.
• But this legitimacy was significantly weakened after the Tiananmen Square massacre in 1989.
• But this performance legitimacy, relying heavily as it does on economic success, contains inherent vulnerabilities that could undermine the regime.

Lukewarm public response

• Outside of official endorsements, the film seems to have received few positive comments within China.
• Significantly, initial responses from two main ideological camps – the Maoists and the Confucianists – have diverged dramatically.
• So this attempt to promote “Xi Jingping thought” to the Chinese public appears to be a hard sell.

Tao Zhang does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.